Aller au contenu principal
← Tous les financements vérifiés
Tier AUS

Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)

National Institutes of Health

Connectez-vous et complétez votre Funding Passport pour voir si vous êtes admissible — un verdict transparent, fondé sur des règles, pas une boîte noire.

Se connecter

À propos de cette possibilité

The goal of this Notice of Funding Opportunity (NOFO) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry; pharmacokinetics (PK); Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET); efficacy in animal models; development of biomarkers for target engagement; formulation development; chemical synthesis under Good Manufacturing Practices (GMP); Investigational New Drug (IND) enabling studies; and initial Phase I clinical testing. Applications not responsive to this NOFO include research on basic mechanisms of disease or mechanisms of drug action; development ofrisk, diagnostic, prognostic, predictive, and preventionbiomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combination therapies; discovery activities such as high-throughput screening and hit optimization; and stand-alone clinical trials.

Documents requis

La source officielle n'indique pas de documents précis ici — vérifiez les exigences avant de postuler.

Source et traçabilité de vérification

Première collecte
20 novembre 2026
Dernière vérification
20 novembre 2026
Empreinte du contenu
b386182ee23c1f37…